|New Threads Only:|
|New Threads & Replies:|
Forum List » Business News and Headlines|
SEC Filings, Earing Reports, Press Releases
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q/A)
Posted by: gurufocus (IP Logged)
Date: February 10, 2012 11:37PM
Ligand Pharmaceuticals Inc. (LGND) filed Amended Quarterly Report for the period ended 2011-09-30. Ligand Pharmaceuticals Inc. has a market cap of $280.7 million; its shares were traded at around $14.9048 with and P/S ratio of 11.9. Ligand Pharmaceuticals Inc. had an annual average earning growth of 7.2% over the past 10 years.
Highlight of Business Operations:General and administrative expenses for the three-month period ended September 30, 2011 have been reduced by $0.2 million to $4.0 million from $4.1 million and general and administrative expenses for the nine-month period ended September 30, 2011 have been reduced by $0.9 million to $11.3 million from $12.1 million ;
This Amended Form 10-Q also includes currently-dated certifications from the Companys Chief Executive Officer and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. The Company has not modified or updated disclosures presented in the Original Form 10-Q, except as required to specifically reflect the effects of the restatement in the Amended Form 10-Q. Accordingly, this Amended Form 10-Q does not reflect other events occurring after the Original Form 10-Q, nor does it modify or update those disclosures affected by other subsequent events. Information not affected by the restatement is unchanged and reflects the disclosures made at the time of the Original Form 10-Q.
Stocks Discussed: LGND,